

May 30, 2023

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

**Trading Symbol: ZOTA**

**Sub: Outcome of Board Meeting held on Tuesday, May 30, 2023**

**Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject we, Zota Health Care Limited (“the Company”) would like to inform you that the Board of Directors of the Company in its meeting held on Tuesday, May 30, 2023 at 2:00 P.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat – 395002, Gujarat, have *inter alia*, discussed and approved the following businesses:

1. Considered and approved standalone and consolidated audited financial results for the quarter and year ended on March 31, 2023 along with Audit Reports thereon. Financial Results and Audit Reports are enclosed herewith (**Annexure - 1**).

We would like to inform you that M/s. Shivangi Parekh & Co, Chartered Accountants, Statutory Auditor of the Company, have issued the Audit Reports with unmodified opinion. Further, standalone and consolidated audited financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at [www.nseindia.com](http://www.nseindia.com) and on Company’s website at [www.zotahealthcare.com](http://www.zotahealthcare.com)

2. Recommended final dividend at the rate of 10% i.e. Rs. 1/- per equity shares of Rs. 10/- each for the financial year 2022-23, subject to the approval of shareholders at the ensuing Annual General meeting of the Company.

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

The Board meeting concluded at 5:00 P.M.

This is for your information and record.

Thanking You,

Yours Faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**

**Place:** Surat

**Encl:** a/a

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601

Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)

Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

**SHIVANGI PAREKH & CO.**

CHARTERED ACCOUNTANTS

---

**Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors of  
ZOTA HEALTH CARE LIMITED

**Report on the audit of the Standalone Financial Results****Opinion**

We have audited the accompanying standalone quarterly and year to date financial results of **ZOTA HEALTH CARE LIMITED** (the "Company") for **the quarter and year ended March 31, 2023** ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net-profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our

opinion.

**Management’s Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company’s financial reporting process.

**Auditor’s Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

# SHIVANGI PAREKH & CO.

## CHARTERED ACCOUNTANTS

---

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence,

# **SHIVANGI PAREKH & CO.**

**CHARTERED ACCOUNTANTS**

---

and where applicable, related safeguards.

## **Other Matters**

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the published figures of the year-to-date (nine months) ended December 31, 2022 , which were subjected to limited review, as required under the Listing Regulations.

**For Shivangi Parekh & Co.  
Chartered Accountants  
ICAI FRN: 131449W**

**Date: 30-05-2023**

**Place: Surat**


**CA. Shivangi Mehta  
Proprietor  
M. No.118936  
UDIN: 23118936BGWQCM5174**


Audited Standalone Financial Results for the Quarter and Year ended 31st March, 2023

(₹ in Lakhs, except per share data)

Particulars	Quarter Ended			Year Ended	
	31-03-2023 (Audited)	31-12-2022 (Unaudited)	31-03-2022 (Audited)	31-03-2023 (Audited)	31-03-2022 (Audited)
I. Revenue from Operations	3625.74	3404.82	3175.26	13836.60	13153.33
II. Other Income	23.50	79.75	82.39	255.87	164.56
III. <b>Total Income</b>	<b>3649.24</b>	<b>3484.57</b>	<b>3257.65</b>	<b>14092.47</b>	<b>13317.89</b>
IV. <b>Expenses:</b>					
Cost of Materials Consumed	320.44	224.02	458.67	1741.40	1996.94
Purchases of Stock-in-Trade	2285.05	2721.38	1629.33	8183.66	6608.42
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(294.22)	(705.29)	258.30	(1099.55)	148.45
Employee Benefit Expenses	387.98	251.10	256.03	1145.07	986.77
Finance Costs	1.07	1.03	3.93	6.33	7.32
Depreciation / Amortisation and Depletion Expense	66.49	62.18	69.84	241.99	273.05
Other Expenses	869.02	898.91	536.75	3065.07	1877.80
<b>Total Expenses</b>	<b>3635.83</b>	<b>3453.32</b>	<b>3212.84</b>	<b>13283.98</b>	<b>11898.75</b>
V. Profit before Exceptional items and tax from continuing operations (III-IV)	13.41	31.25	44.81	808.50	1419.14
VI. Exceptional Items	53.79	-	-	53.79	-
VII. Profit/(loss) before tax	67.20	31.25	44.81	862.29	1419.14
VIII. Tax Expense:					
(1) Current tax	16.32	8.65	17.60	214.67	369.03
(1.1) I.T. & DD Tax Provision Created Short/ excess	(9.99)	-	(0.18)	(9.99)	(0.18)
(2) Deferred Tax	4.54	2.54	7.35	1.75	7.71
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	65.41	25.13	34.74	659.35	1058.01
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-
XIII. <b>Profit/ (Loss) for the period</b>	<b>65.41</b>	<b>25.13</b>	<b>34.74</b>	<b>659.35</b>	<b>1058.01</b>
XIV. <b>Other Comprehensive Income</b>					
A (i) Items that will not be reclassified to Statement of profit and loss	27.24	(5.28)	8.34	35.97	18.48
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(6.86)	1.33	(2.10)	(9.05)	(4.65)
B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-
Other comprehensive income for the period, net of tax	20.38	(3.95)	6.24	26.92	13.83
<b>Total comprehensive income for the period (XIII + XIV)</b>	<b>85.79</b>	<b>21.19</b>	<b>40.98</b>	<b>686.27</b>	<b>1071.84</b>
Paid-up Equity Share Capital	2516.03	2516.03	2516.03	2516.03	2516.03
Other Equity	-	-	-	6930.28	6621.42
Earnings per equity share of face value of ₹ 10 each					
(1) Basic (in ₹)	0.26	0.10	0.14	2.62	4.25
(2) Diluted (in ₹)	0.26	0.10	0.14	2.62	4.25

\* denotes figures less than a lakh  
For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
(Whole Time Director)  
Manukant C. Zota  
(Din : 02267804)

  
Company Secretary  
Ashvin Variya

  
Chief Financial Officer  
Viral Mandviwala

  
Chief Executive Officer  
Sujit Paul



For Shivangi Parekh & Co.  
Chartered Accountants  
Firm No. 131449W

CA. Shivangi Mehta  
Proprietor  
M. No. 118936

Date: 30-05-2023  
Place : Surat

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

	PARTICULARS	For the Year Ended on 31st March, 2023	For the Year Ended on 31st March, 2022
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit Before Tax as per Statement of Profit and Loss	862.29	1419.14
	Adjusted for:		
	Exceptional items	(53.79)	-
	Depreciation / Amortisation and Depletion Expense	241.99	273.05
	Finance Costs	1.37	1.32
	Interest Income	(138.63)	(128.71)
	<b>Operating Profit before Working Capital Changes and other adjustments:</b>	<b>913.23</b>	<b>1564.80</b>
	Adjusted for:		
	Inventories	(785.59)	14.93
	Trade Receivables	(524.92)	(947.21)
	Trade Payables	650.76	272.70
	Other Current Liabilities and Provisions	(978.84)	1213.44
	Provisions - Non-Current	(9.03)	8.41
	Current Financial Assets	111.84	(491.37)
	Other Current Assets	(192.92)	104.04
	<b>Changes in Working Capital</b>	<b>(1728.71)</b>	<b>174.95</b>
	<b>Cash Generated from Operations</b>	<b>(815.48)</b>	<b>1739.76</b>
	Direct Taxes Paid	(213.74)	(373.50)
	<b>Net Cash Flow from/(used in) Operating Activities</b>	<b>(1029.22)</b>	<b>1366.26</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Acquisition of property, plant and equipment, capital work-in-progress and intangible assets	(500.77)	(125.72)
	Proceeds from disposal of Property, Plant and Equipment	113.79	-
	Decrease in Long Term Loans & Advances	(1006.32)	(224.09)
	Interest Received	138.63	128.71
	Non-current Investments	2530.30	(2484.77)
	<b>Net Cash Flow from/(used in) Investing Activities</b>	<b>1275.63</b>	<b>(2705.86)</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Proceeds from Issue of Equity Share Capital	-	60.00
	Increase in Securities Premium Reserve	-	1620.00
	Finance Costs paid	(1.37)	(1.32)
	Dividend Paid	(377.40)	(251.60)
	<b>Net Cash Flow from / (used in) Financing Activities</b>	<b>(378.78)</b>	<b>1427.08</b>
	<b>Net Increase/(Decrease) in Cash &amp; Cash Equivalents</b>	<b>(132.36)</b>	<b>87.47</b>
	Opening Balance of Cash and Cash Equivalents	220.00	132.52
	<b>Closing Balance of Cash and Cash Equivalents</b>	<b>87.63</b>	<b>220.00</b>

For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
(Whole Time Director)  
Manukant C. Zota  
(Din : 02267804)

  
Company Secretary  
Ashvin Variya

  
Chief Financial Officer  
Viral Mandviwala

  
Chief Executive Officer  
Sujit Paul



For Shivangi Parekh & Co.  
Chartered Accountants

CA. Shivangi Mehta  
Proprietor  
M. No. 118936  
Firm No. 131449W

Date: 30-05-2023  
Place: Surat

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

# SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

---

## Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
The Board of Directors of  
ZOTA HEALTH CARE LIMITED

### Report on the audit of the Consolidated Financial Results

#### Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **ZOTA HEALTH CARE LIMITED** ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for **the quarter and year ended March 31, 2023** ("the Statement"), attached herewith, being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements of subsidiaries, the Statement:

- a. includes the results of the following entities:
  - Zota Health Care Limited (Parent)
  - Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
  - Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net-profit/(loss) and other comprehensive income) and other financial information of the Group for the quarter and year ended March 31, 2023.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

# SHIVANGI PAREKH & CO.

## CHARTERED ACCOUNTANTS

---

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Management’s Responsibilities for the Consolidated Financial Results**

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net-profit and other comprehensive income and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor’s Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

# SHIVANGI PAREKH & CO.

## CHARTERED ACCOUNTANTS

---

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence,

# SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

---

and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

## **Other Matters**

The Statement includes the audited Financial Statements of 2 subsidiaries, whose financial statements reflect total assets of Rs. 6515.92 Lakhs as at March 31, 2023 and total revenues of Rs. 1461.60 Lakhs, total net loss of Rs. 1129.11 lakhs and total comprehensive loss of Rs. 1128.38 lakhs and cash inflows (net) Rs. 13.90 lakhs for the year ended March 31 2023, as considered in the consolidated financial results, which have been audited by their respective independent auditors.

The independent auditors' reports on interim financial statements of these entities have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results certified by the Board of Directors.

Further, in addendum to paragraph 1 of this report, we report that the figures for the quarter ended March 31, 2023 represents the derived figures between the audited figures of the financial year ended March 31, 2023 and the published figures of the year-to-date (nine months) ended December 31, 2022 , which were subjected to limited review.

**For Shivangi Parekh & Co.**  
**Chartered Accountants**  
**ICAI FRN: 131449W**

**Date: 30-05-2023**

**Place: Surat**

**CA. Shivangi Mehta**  
**Proprietor**  
**M. No.118936**  
**UDIN: 23118936BGWQCN5801**

healthcare Ltd.		Quarter Ended			Year Ended	
		31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
	Particulars					
I.	Revenue from Operations	3684.89	3496.59	3133.64	13995.69	13119.31
II.	Other Income	2.50	61.73	81.26	195.61	163.04
III.	<b>Total Income</b>	<b>3687.39</b>	<b>3558.32</b>	<b>3214.90</b>	<b>14191.30</b>	<b>13282.35</b>
IV.	<b>Expenses:</b>					
	Cost of Materials Consumed	320.44	224.02	458.67	1741.40	1996.94
	Purchases of Stock-in-Trade	2285.05	2721.38	1629.33	8183.66	6608.42
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(536.89)	(801.59)	194.16	(1598.09)	56.39
	Employee Benefit Expenses	450.24	288.24	271.30	1291.36	1024.42
	Finance Costs	81.31	70.88	28.50	256.35	32.07
	Depreciation / Amortisation and Depletion Expense	387.59	330.18	158.00	1195.71	367.13
	Other Expenses	1062.84	1061.89	574.37	3643.79	1953.48
	<b>Total Expenses</b>	<b>4050.57</b>	<b>3895.00</b>	<b>3314.33</b>	<b>14714.19</b>	<b>12038.87</b>
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	(363.18)	(336.69)	(99.43)	(522.89)	1243.48
VI.	Exceptional Items	53.79	-	-	53.79	-
VII.	Profit/(loss) before tax	(309.39)	(336.69)	(99.43)	(469.10)	1243.48
VIII.	Tax Expense:					
	(1) Current tax	16.32	8.65	17.60	214.67	369.03
	(1.1) I.T. & DD Tax Provision Created Short/ excess	(9.99)	-	(0.18)	(9.99)	(0.18)
	(2) Deferred Tax	52.25	22.80	15.77	96.51	16.13
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(263.48)	(322.54)	(101.09)	(577.28)	890.76
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-
XIII.	<b>Profit/ (Loss) for the period</b>	<b>(263.48)</b>	<b>(322.54)</b>	<b>(101.09)</b>	<b>(577.28)</b>	<b>890.76</b>
XIV.	<b>Other Comprehensive Income</b>					
	A (i) Items that will not be reclassified to Statement of profit and loss	28.30	(5.28)	8.34	37.03	18.48
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(7.12)	1.33	(2.10)	(9.32)	(4.65)
	B (i) Items that will be reclassified to Statement of profit and loss	(0.13)	0.02	0.08	(0.06)	*
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.03	(0.00)	(0.02)	0.02	*
	Other comprehensive income for the period, net of tax	21.08	(3.94)	6.30	27.67	13.83
	<b>Total comprehensive income for the period (XIII + XIV)</b>	<b>(242.40)</b>	<b>(326.47)</b>	<b>(94.78)</b>	<b>(549.61)</b>	<b>904.59</b>
	Profit attributable to:					
	Owners of the parent	(263.48)	(322.54)	(101.09)	(577.28)	890.76
	Non-controlling interest	-	-	-	-	-
	Other comprehensive income attributable to:					
	Owners of the parent	21.08	(3.94)	6.30	27.67	13.83
	Non-controlling interest	-	-	-	-	-
	<b>Total Comprehensive Income attributable to:</b>					
	Owners of the parent	(242.40)	(326.47)	(94.78)	(549.61)	904.59
	Non-controlling interest	-	-	-	-	-
	Paid-up Equity Share Capital	2516.03	2516.03	2516.03	2516.03	2516.03
	Other Equity	-	-	-	5519.64	6446.65
	Earnings per equity share of face value of ₹ 10 each					
	(1) Basic (in ₹)	(1.05)	(1.28)	(0.40)	(2.29)	3.58
	(2) Diluted (in ₹)	(1.05)	(1.28)	(0.40)	(2.29)	3.58

\* denotes figures less than a lakh  
For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
(Whole Time Director)  
Manukant C. Zota  
(Din : 02267804)

  
Company Secretary  
Ashvin Variya

  
Chief Financial Officer  
Viral Mandviwala

  
Chief Executive Officer  
Sujit Paul



For Shivangi Parekh & Co.  
Chartered Accountants  
Firm No. 131449W

CA. Shivangi Mehta  
Proprietor  
M. No. 118936

**Registered Office**

Date: 30-05-2023  
Place : Surat  
Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

healthcare ltd.			
	PARTICULARS	For the Year Ended on 31st March, 2023	For the Year Ended on 31st March, 2022
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit Before Tax as per Statement of Profit and Loss	-469.10	1243.48
	Adjusted for:		
	Exceptional items	-53.79	-
	Depreciation / Amortisation and Depletion Expense	1195.71	367.13
	Finance Costs	247.37	25.69
	Interest Income	-77.72	-126.65
	<b>Operating Profit before Working Capital Changes</b>	<b>842.46</b>	<b>1509.66</b>
	Adjusted for:		
	Inventories	-1284.13	-77.12
	Trade Receivables	-529.52	-947.60
	Trade Payables	2159.56	497.79
	Other Current Liabilities and Provisions	-810.07	1239.60
	Provisions - Non-Current	-9.03	8.41
	Current Financial Assets	111.84	-491.37
	Other Current Assets	-467.71	-32.66
	<b>Changes in Working Capital</b>	<b>-829.07</b>	<b>197.05</b>
	<b>Cash Generated from Operations</b>	<b>13.39</b>	<b>1706.70</b>
	Taxes Paid	-214.00	-373.50
	<b>Net Cash Flow from/(Used in) Operating Activities (A)</b>	<b>-200.61</b>	<b>1333.20</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Acquisition of property, plant and equipment, capital work-in-progress and intangible assets	-1249.92	-324.80
	Proceeds from disposal of Property, Plant and Equipment	113.79	-
	Decrease in Long Term Loans & Advances	-1.54	17.38
	Interest Received	77.72	126.65
	Non-current Investments	2530.30	-2484.43
	<b>Net Cash Flow (Used in) Investing Activities (B)</b>	<b>1470.35</b>	<b>-2665.20</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Proceeds from Issue of Equity Share Capital	-	250.00
	Increase in Securities Premium Reserve	-	1620.00
	Principal payment of lease liability	-591.38	-51.36
	Interest payment of lease liability	-245.99	-24.37
	Finance Costs	-1.37	-1.32
	Loans	-171.99	-114.02
	Dividend Paid	-377.40	-251.60
	<b>Net Cash Flow from / (Used in) Financing Activities (C)</b>	<b>-1388.14</b>	<b>1427.33</b>
	<b>Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>-118.40</b>	<b>95.34</b>
	Effect of Exchange differences on cash and cash equivalents held in foreign currency	-0.01	-0.05
	Opening Balance of Cash and Cash Equivalents	229.91	134.63
	Closing Balance of Cash and Cash Equivalents	<b>111.50</b>	<b>229.91</b>

As per our report of even date  
For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
(Whole Time Director)  
Manukant C. Zota  
(Din : 02267804)

  
Company Secretary  
Ashvin Variya

  
Chief Financial Officer  
Viral Mandviwala

  
Chief Executive Officer  
Sujit Paul



For Shivangi Parekh & Co.  
Chartered Accountants  
Firm No. 131449W

CA. Shivangi Mehta  
Proprietor  
M. No. 118936

Date: 30-05-2023

Place: Surat

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

1. The above financial results for the quarter and year ended March 31, 2023 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 30, 2023.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The figures for quarter ended March 31, 2023 are balancing figures between the audited figures of the financial year ended March 31, 2023 and the published figures of the year-to-date (nine months) ended December 31, 2022, which were subjected to limited review report.
4. The Statutory Auditors have provided Standalone and Consolidated Audit Reports for the quarter and year ended March 31, 2023 with unmodified option.
5. The Board of Directors has recommended dividend at the rate of 10% i.e. Re. 1/- per equity share of Rs. 10/- each for the financial year 2022-23, which is subject to approval of the members in ensuing Annual General Meeting.
6. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
7. The consolidated results include the result of following wholly owned subsidiaries:
  - (i) DAVAINdia HEALTH MART LIMITED
  - (ii) Zota Healthcare Lanka (Pvt) Ltd
8. The code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September, 2020. The code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is in the process of assessing the impact of the Code and will record the same, if any, in the year the Code becomes effective.
9. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 4304.72 lakhs and a corresponding Lease Liability of Rs. 4510.07 lakhs as at March 31, 2023. The impact of this on the consolidated profit for the quarter and year ended March 31, 2023 is Rs. 52.63 lakhs and Rs. 184.86 lakhs respectively.
10. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122



Particulars	Standalone		Consolidated	
	As at 31st March, 2023 Audited	As at 31st March, 2022 Audited	As at 31st March, 2023 Audited	As at 31st March, 2022 Audited
<b>ASSETS</b>				
(1) <b>Non-Current Assets</b>				
Property, plant and equipment	715.19	708.63	1472.07	893.84
Right-of-use assets	-	-	4306.82	1469.56
Intangible Assets	429.40	546.88	429.40	546.88
Capital work-in-progress	309.70	-	309.70	-
Intangible assets under development	-	-	-	-
Financial Assets				
(i) Investments	953.87	3484.17	753.38	3283.65
(iii) Loans	1267.30	260.98	11.02	9.48
Deferred tax assets (Net)	8.45	6.70	111.97	15.46
Other Non-current assets	-	-	-	-
<b>Total Non-Current assets</b>	<b>3683.91</b>	<b>5007.36</b>	<b>7394.36</b>	<b>6218.87</b>
(2) <b>Current Assets</b>				
Inventories	3583.46	2797.86	4178.81	2894.68
Financial Assets				
(i) Trade Receivables	4356.46	3831.54	2782.89	3636.63
(ii) Cash and Cash Equivalents	0.74	0.96	9.19	3.82
(iii) Bank balance other than cash and cash equivalents	86.89	219.03	102.31	226.09
(iv) Loans	552.92	664.75	730.32	783.63
Other Current Assets	199.34	6.42	613.33	145.61
<b>Total Current assets</b>	<b>8779.80</b>	<b>7520.57</b>	<b>8416.85</b>	<b>7690.47</b>
<b>Total Assets</b>	<b>12463.71</b>	<b>12527.93</b>	<b>15811.20</b>	<b>13909.35</b>
<b>EQUITY AND LIABILITIES</b>				
(1) <b>Equity</b>				
(i) Equity Share capital	2516.03	2516.03	2516.03	2516.03
(ii) Other Equity	6930.28	6621.42	5519.64	6446.65
<b>Total Equity (Refer Note 1)</b>	<b>9446.31</b>	<b>9137.45</b>	<b>8035.67</b>	<b>8962.69</b>
(2) <b>Liabilities</b>				
<b>Non-Current Liabilities</b>				
Financial Liabilities				
(i) Borrowings	-	-	-	-
(ii) Lease liabilities	-	-	3626.31	1246.32
Provisions	93.83	102.86	97.64	104.25
<b>Total non-current liabilities</b>	<b>93.83</b>	<b>102.86</b>	<b>3723.95</b>	<b>1350.58</b>
<b>Current liabilities</b>				
Financial Liabilities				
(i) Borrowings	-	-	-	-
(ii) Lease liabilities	-	-	885.87	243.73
(ii) Trade payables	-	-	-	-
- Total outstanding dues of micro enterprises and small enterprises	46.03	64.62	46.03	64.62
- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	2436.23	1766.89	2599.96	1805.08
Other Current liabilities	94.51	1000.18	146.16	1019.51
Provisions	346.80	455.94	373.56	463.14
<b>Total current liabilities</b>	<b>2923.57</b>	<b>3287.63</b>	<b>4051.58</b>	<b>3596.08</b>
<b>Total Liabilities</b>	<b>3017.40</b>	<b>3390.48</b>	<b>7775.53</b>	<b>4946.66</b>
<b>Total Equity and Liabilities</b>	<b>12463.71</b>	<b>12527.93</b>	<b>15811.20</b>	<b>13909.35</b>

Note:

- 1 Since the subsidiary companies are Wholly Owned Subsidiaries, the non controlling interests is Nil in case of Consolidated Financial Statements and thus, Equity attributable to owners of the Company shall be the same as total equity.

For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
(Whole Time Director)  
Manukant C. Zota  
(Din : 02267804)

  
Company Secretary  
Ashvin Variya

  
Chief Financial Officer  
Viral Mandviwala

  
Chief Executive Officer  
Sujit Paul



For Shivangi Parekh & Co.  
Chartered Accountants  
Firm No. 131449W

CA. Shivangi Mehta  
Proprietor  
M. No. 118936

Date: 30-05-2023  
Place : Surat

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

May 30, 2023

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400051

Dear Sir/ Madam,

**Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 in respect of Audit Reports with unmodified opinion**

I, Himanshu Zota, Whole-time Director of Zota Health Care Limited, hereby declare that M/s Shivangi Parekh & Co., Chartered Accountants (Firm Reg. No. 131449W), Statutory Auditors of the Company have issued Audit Reports with unmodified opinion on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023.

This declaration is being given in accordance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended, and SEBI Circular No.: CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this on your record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

*Himanshu Zota*

**Himanshu Zota**  
**(Whole-time Director)**  
**DIN: 01097722**



**Place: Surat**

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122